Brain damage cases force an FDA hold on Bellicum's lead cell therapy -- shares tank
Bellicum Pharmaceuticals $BLCM just fell even further behind the pack leaders in the cell therapy crowd.
The Houston-based biotech reported after the markets closed Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
